Pharmacokinetics and Pharmacodynamics Study of Oral Salmon Calcitonin in Healthy Postmenopausal Women

This study has been completed.
Information provided by:
Novartis Identifier:
First received: December 11, 2006
Last updated: NA
Last verified: December 2006
History: No changes posted
This is a phase I study to analyze bioavailability and pharmacodynamic of two different variants of oral salmon calcitonin (SMC021) in postmenopausal women

Condition Intervention Phase
Postmenopausal Osteoporosis
Drug: Oral salmon calcitonin
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacokinetics/Dynamics Study
Intervention Model: Crossover Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Double-Blind, Double-Dummy, Randomized, Placebo-Controlled Crossover Phase I Study Assessing Pharmacokinetics and Pharmacodynamics of Two Different SMC021 0.8 mg Variants and the Effect of Timing of Drug Intake in Healthy Postmenopausal Women

Resource links provided by NLM:

Further study details as provided by Novartis:

Primary Outcome Measures:
  • Pharmacokinetic profile of the new variant compared to the current variant on Day 1
  • Effect on bone resorption biomarker on Day 1

Secondary Outcome Measures:
  • Effect on bone resorption biomarker 24 hours after the last dosing on Day 3
  • Effect on bone resorption biomarker after drug intake at different timepoints
  • Effect of dosing at different timepoints on the pharmacokinetic profile

Estimated Enrollment: 86
Study Start Date: August 2006
Estimated Study Completion Date: November 2006

Ages Eligible for Study:   40 Years to 70 Years
Genders Eligible for Study:   Female

Inclusion Criteria:

  • Healthy postmenopausal women

Exclusion Criteria:

  • Previous treatment with other osteoporosis medication

Other protocol-defined inclusion/exclusion criteria may apply.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00411125

Copenhagen, Denmark
Sponsors and Collaborators
Study Director: Novartis Basel Novartis Basel +41 61 324 1111
  More Information

No publications provided by Novartis

Additional publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00411125     History of Changes
Other Study ID Numbers: CSMC021A2111 
Study First Received: December 11, 2006
Last Updated: December 11, 2006
Health Authority: Denmark: Danish Medicines Agency

Keywords provided by Novartis:

Additional relevant MeSH terms:
Osteoporosis, Postmenopausal
Bone Diseases
Bone Diseases, Metabolic
Musculoskeletal Diseases
Calcitonin Gene-Related Peptide
Salmon calcitonin
Bone Density Conservation Agents
Cardiovascular Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Vasodilator Agents processed this record on February 04, 2016